Fresolimumab

Drug Profile

Fresolimumab

Alternative Names: GC-1008

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Baylor College of Medicine; Genzyme Corporation; Sanofi Genzyme
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteogenesis imperfecta
  • No development reported Fibrosis; Malignant melanoma; Pulmonary fibrosis; Renal cancer
  • Discontinued Focal segmental glomerulosclerosis

Most Recent Events

  • 15 Jul 2017 Phase-I clinical trials in Osteogenesis imperfecta in USA (IV) (NCT03064074)
  • 27 Feb 2017 Baylor College of Medicine in collaboration with Genzyme plans a phase I trial for Osteogenesis imperfecta in USA (NCT03064074)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top